Nascent Pharma Holdings, Inc. (NASC) Stock Analysis
For informational purposes only. Not financial advice. Analysis by Sedat ANAK, Founder & Editor-in-Chief | AI-powered analysis. Data sourced from SEC filings and institutional-grade financial providers. Editorially reviewed. Not financial advice.
Nascent Pharma Holdings, Inc. (NASC) trades at $0.009. Nascent Pharma Holdings, Inc. focuses on the protection and commercialization of cannabis patents and produces superfood drink mix products. The company, formerly known as Can B Corp. Sector: Healthcare.
Price as of Aug 20, 2026 · Last analyzed: Mar 16, 2026Analyst Coverage for NASC: NASC does not currently have published analyst price targets in our coverage universe. This is common for smaller-cap names with limited Wall Street coverage. In the absence of analyst consensus, our AI model evaluates NASC against Healthcare peers across nine fundamental dimensions and assigns an underweight signal based on the underlying data.
NASC: 1/3 scored disciplines lean bearish. Dominant signal: Ken Griffin bearish.
How is this calculated? →Nascent Pharma Holdings, Inc. (NASC) Healthcare & Pipeline Overview
Nascent Pharma Holdings, Inc., operating in the healthcare sector, focuses on cannabis patent protection and commercialization, alongside producing superfood drink mixes under the Longevity brand. Formerly Can B Corp., the company's small size and OTC listing present unique investment considerations within the specialty and generic drug market.
What Is the Investment Thesis for NASC?
Investing in Nascent Pharma Holdings, Inc. presents a speculative opportunity given its small market capitalization and OTC listing. The company's focus on cannabis patent protection offers potential upside if it can successfully monetize its intellectual property. However, the company's negative gross margin of -33.2% indicates significant challenges in its current operations. A key value driver will be the successful commercialization of its cannabis patents and the growth of its Longevity superfood drink mix product line. The company's beta of 0.62 suggests lower volatility compared to the broader market. Investors should closely monitor the company's ability to improve its gross margin, generate positive free cash flow, and secure strategic partnerships to drive growth. The absence of a dividend means investors are relying solely on capital appreciation.
Based on FMP financials and quantitative analysis
NASC Key Highlights
Market capitalization of $0.00B indicates a micro-cap company with high growth potential but also significant risk.
- Gross margin of -33.2% signals operational inefficiencies and challenges in pricing or cost management.
- Free cash flow of $0.00B suggests the company is not currently generating positive cash flow from its operations.
- Beta of 0.62 indicates lower volatility compared to the overall market, potentially appealing to risk-averse investors.
- The company operates in the cannabis patent and superfood drink mix markets, offering exposure to high-growth sectors within the healthcare and wellness industries.
Who Are NASC's Competitors?
NASC is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.
| Company | Price | Change | Market Cap | AI Score |
|---|---|---|---|---|
| INNPF INNOCAN PHARMA Corp | $1.60 | -8.05% | $7.20M | 61 |
| GENH Generation Hemp, Inc. | $0.22 | +0.00% | $25.3M | 63 |
| GBLP Global Pharmatech, Inc. | $0.08 | +0.00% | $33.3M | 62 |
| ETST Earth Science Tech, Inc. | $0.12 | +14.45% | $35.3M | 61 |
| GDNSF Goodness Growth Holdings, Inc. | $0.45 | +0.00% | $61.1M | 64 |
| MNNGF Baijin Life Science Holdings Limited | $0.08 | +0.00% | $74.6M | 63 |
| SHIEF Shield Therapeutics plc | $0.07 | +0.00% | $75.3M | 62 |
| CNVCF BioHarvest Sciences Inc. | $6.30 | +0.00% | $109M | 66 |
AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance
What Are NASC's Key Strengths?
Focus on cannabis patent protection.
- Superfood drink mix product line.
- Strategic shift towards higher-growth sectors.
- Lean organizational structure with 12 employees.
What Are NASC's Weaknesses?
Negative gross margin of -33.2%.
- Small market capitalization of $0.00B.
- OTC listing indicates higher risk and lower liquidity.
- Limited financial resources.
What Could Drive NASC Stock Higher?
Potential licensing agreements for cannabis patents could generate revenue.
- Launch of new Longevity superfood drink mix products could drive sales growth.
- Increasing legalization of cannabis could create new market opportunities.
- Growing consumer demand for health and wellness products could boost sales.
- Strategic partnerships with established companies could provide access to capital and distribution networks.
What Are the Key Risks for NASC?
Weak fundamentals — a Piotroski F-Score of 3/9 flags soft profitability, leverage or efficiency.
- Negative gross margin may persist, hindering profitability.
- Limited financial resources may constrain growth opportunities.
- Intense competition in the superfood and cannabis markets could erode market share.
- OTC listing indicates higher risk and lower liquidity.
- Changing cannabis regulations could negatively impact the company's business.
What Are the Growth Opportunities for NASC?
- Expansion of the Longevity Brand: The superfood drink mix market is experiencing significant growth, driven by increasing consumer interest in health and wellness. Nascent Pharma Holdings can capitalize on this trend by expanding its Longevity product line, developing new flavors and formulations, and increasing its distribution channels. The global superfood market is projected to reach $200 billion by 2028, providing a large addressable market for the company. Success hinges on effective marketing and product differentiation.
- Monetization of Cannabis Patents: The increasing legalization of cannabis creates opportunities for Nascent Pharma Holdings to monetize its cannabis patents through licensing agreements or strategic partnerships. The global cannabis market is projected to reach $90.4 billion by 2026. Successful patent monetization could generate significant revenue streams for the company, but it requires effective enforcement of its intellectual property rights and navigating complex regulatory landscapes.
- Strategic Partnerships: Forming strategic partnerships with established pharmaceutical companies or cannabis businesses can provide Nascent Pharma Holdings with access to capital, distribution networks, and expertise. These partnerships can accelerate the commercialization of its products and patents. Identifying and securing suitable partners is crucial for this growth strategy.
- Geographic Expansion: Expanding its operations into new geographic markets can drive revenue growth for Nascent Pharma Holdings. The company can target regions with high demand for superfood drink mixes and favorable cannabis regulations. Successful geographic expansion requires careful market research and adaptation to local consumer preferences.
- Development of New Products: Investing in research and development to create new and innovative products can drive long-term growth for Nascent Pharma Holdings. The company can focus on developing new superfood formulations, cannabis-based products, or other health and wellness offerings. Successful product development requires a deep understanding of market trends and consumer needs.
What Are NASC's Competitive Advantages?
- Patent portfolio in the cannabis sector (if patents are strong and defensible).
- Brand recognition for Longevity superfood drink mix products (if brand is well-established).
- Proprietary formulations for superfood drink mixes (if formulations are unique and difficult to replicate).
What Does NASC Do?
Nascent Pharma Holdings, Inc., incorporated in 2005 and based in Hicksville, New York, operates within the healthcare sector, specifically in the specialty and generic drug manufacturing industry. Originally known as Can B Corp., the company rebranded in September 2025 to Nascent Pharma Holdings, Inc., signaling a shift in its strategic focus. The company's core activities involve the protection and commercialization of cannabis patents, indicating an interest in the burgeoning cannabis market and intellectual property rights within this space. In addition to its patent-related activities, Nascent Pharma Holdings produces superfood drink mix products under the Longevity brand, diversifying its revenue streams and targeting health-conscious consumers. With a small team of 12 employees, the company operates on a lean structure. Its business model encompasses both the potentially high-margin area of cannabis patent management and the consumer-facing market of health and wellness products. Nascent Pharma Holdings' evolution from Can B Corp. to its current form reflects an adaptation to market opportunities and a strategic realignment towards higher-growth sectors within the healthcare and wellness industries.
What Products and Services Does NASC Offer?
- Protects and commercializes cannabis patents.
- Produces superfood drink mix products under the Longevity brand.
- Operates in the healthcare sector, specifically in the specialty and generic drug manufacturing industry.
- Focuses on intellectual property rights within the cannabis market.
- Targets health-conscious consumers with its Longevity product line.
- Adapts to market opportunities and strategic realignments towards higher-growth sectors.
How Does NASC Make Money?
- Generates revenue through the sale of Longevity superfood drink mix products.
- Seeks to generate revenue through licensing or sale of cannabis patents.
- Focuses on protecting and monetizing intellectual property in the cannabis sector.
What Industry Does NASC Operate In?
Nascent Pharma Holdings, Inc. operates in the specialty and generic drug manufacturing industry, which is experiencing growth driven by increasing demand for affordable medications and health and wellness products. The cannabis market, in particular, is expanding rapidly as more jurisdictions legalize cannabis for medical and recreational use. This creates opportunities for companies like Nascent Pharma Holdings to capitalize on cannabis-related intellectual property. However, the industry is also highly competitive, with established pharmaceutical companies and emerging cannabis businesses vying for market share. Nascent Pharma Holdings' success will depend on its ability to differentiate itself through innovative products, effective patent protection, and strategic partnerships.
Who Are NASC's Key Customers?
- Health-conscious consumers seeking superfood drink mixes.
- Potential licensees or buyers of cannabis patents.
- Strategic partners in the pharmaceutical or cannabis industries.
Insider Activity
The most recent 8 insider filings for Nascent Pharma Holdings, Inc. break down as 8 sales and 0 purchases. On net that is roughly 100K shares disposed (about $3K), a signal worth weighing alongside the fundamentals.
Key Financial Metrics
Return on equity for Nascent Pharma Holdings, Inc. stands at 37.6%, a gauge of how efficiently it converts shareholder capital into profit. Its free cash flow yield is -20.4%, a gauge of the cash the business throws off relative to its market value. A current ratio of 0.01 means current liabilities exceed short-term assets, a liquidity point worth watching.
Financial Health
Nascent Pharma Holdings, Inc.'s Piotroski F-Score is 3/9, a 9-point checklist of profitability, leverage and efficiency — flagging fundamental weakness worth scrutiny.
Forward Outlook
Wall Street analysts project Nascent Pharma Holdings, Inc. revenue of about $7.1M for fiscal 2026, with EPS near $-6.30.
Company Profile
Nascent Pharma Holdings, Inc. operates in the Drug Manufacturers - Specialty & Generic industry within the Healthcare sector. It is headquartered in Hicksville, US. The company is led by CEO Marco Alfonsi. NASC has traded publicly since 2012.
NASC Financials
Fundamental Snapshot
Based on FMP financials and quantitative analysis · FY 2025
Bull Case vs Bear Case
Bull Case
- Recent insider buying suggests confidence in the company's future, indicating that executives believe in the potential growth of Nascent Pharma.
- Community sentiment has shifted positively, with discussions highlighting the innovative pipeline and potential breakthroughs in treatments.
- Recent news about strategic partnerships has generated excitement, enhancing the company's credibility and market reach.
- The overall market perception is improving as investors are looking for opportunities in the biotech sector, favoring companies like Nascent with promising prospects.
Bear Case
- Concerns about regulatory hurdles remain prevalent, with some investors worried about the lengthy approval processes for new drugs.
- Social sentiment has shown skepticism regarding the company's ability to deliver on its ambitious timelines, causing hesitation among some traders.
- Recent competition in the biotech space has intensified, leading to fears that Nascent may struggle to differentiate itself effectively.
- Market volatility has led to cautious trading behavior, with many investors preferring to wait for clearer signals before committing to positions in the stock.
AI-generated arguments based on insider flow, news sentiment and technicals — not financial advice · March 2026
NASC Latest News
No recent news available for NASC.
NASC Analyst Consensus
Consensus Rating
Aggregated Buy/Hold/Sell recommendations from Benzinga, Yahoo Finance, and Finnhub for NASC.
Price Targets
Wall Street price target analysis for NASC.
NASC MoonshotScore
What does this score mean?
The MoonshotScore rates NASC 0-100 on quantitative fundamentals — growth, financial health, valuation, momentum, and risk.
NASC OTC Market Information
The OTC Other tier represents the lowest tier of the OTC market, encompassing securities that are not eligible for quotation on OTCQX or OTCQB. Companies in this tier may have limited or no financial disclosure, and they may not meet minimum financial standards. Investing in OTC Other securities carries significant risks due to the potential for fraud, lack of liquidity, and limited information availability. These securities are often considered highly speculative and are subject to less regulatory oversight than those traded on major exchanges like the NYSE or NASDAQ.
- OTC Tier: OTC Other
- Limited or no financial disclosure.
- Low liquidity and wide bid-ask spreads.
- Potential for fraud and price manipulation.
- Limited regulatory oversight.
- High price volatility.
- Verify the company's legal standing and registration.
- Review any available financial statements and disclosures.
- Assess the company's business model and competitive landscape.
- Evaluate the company's management team and track record.
- Understand the risks associated with investing in OTC Other securities.
- Consult with a financial advisor before investing.
- Check for any regulatory actions or legal issues.
- Longevity brand presence indicates some business activity.
- Company has been incorporated since 2005.
- Focus on cannabis patents suggests potential intellectual property value.
Nascent Pharma Holdings, Inc. Healthcare Stock: Key Questions Answered
What does Nascent Pharma Holdings, Inc. do?
Nascent Pharma Holdings, Inc. operates in the healthcare sector, focusing on two primary areas: the protection and commercialization of cannabis patents, and the production of superfood drink mix products under the Longevity brand. The company aims to capitalize on the growing cannabis market through its intellectual property assets, while also targeting health-conscious consumers with its Longevity product line.
What do analysts say about NASC stock?
As of March 16, 2026, formal analyst coverage of Nascent Pharma Holdings, Inc. (NASC) is limited, likely due to its small market capitalization and OTC listing. Key valuation metrics, such as price-to-earnings ratio and price-to-sales ratio, may not be readily available or reliable due to the company's financial performance.
What are the main risks for NASC?
Nascent Pharma Holdings, Inc. faces several key risks, including its negative gross margin, which indicates operational inefficiencies. The company's small market capitalization and OTC listing contribute to higher risk and lower liquidity. Intense competition in the superfood and cannabis markets could erode market share. Changing cannabis regulations could negatively impact the company's business.
What are the key factors to evaluate for NASC?
Evaluate NASC on fundamentals, analyst consensus, and risk factors. Investing in Nascent Pharma Holdings, Inc. presents a speculative opportunity given its small market capitalization and OTC listing. Not financial advice.
How frequently does NASC data refresh on this page?
NASC's price was last updated on Aug 20, 2026 and refreshes on page view during U.S. market hours — it is not a real-time exchange feed. Fundamentals update after quarterly filings; the MoonshotScore recalculates nightly; news aggregates continuously.
What has driven NASC's recent stock price performance?
Nascent Pharma Holdings, Inc. (NASC) moves on earnings results, analyst revisions, sector rotation, and market sentiment. Notable catalyst: Focus on cannabis patent protection. See the News tab for the latest drivers. Past performance does not predict future results.
Should investors consider NASC overvalued or undervalued right now?
Nascent Pharma Holdings, Inc. (NASC) has no trailing P/E available here, so lean on price-to-sales and cash flow in the Financials tab. Compare P/E, P/S, and EV/EBITDA against sector peers for a full view.
How do I research NASC before investing?
Before investing in Nascent Pharma Holdings, Inc. (NASC), research these four areas: (1) the company's revenue model and competitive position (see Company Overview), (2) financial health through revenue growth, margins, and cash flow (see MoonshotScore), (3) analyst consensus ratings and price targets (see Analyst tab), and (4) specific risk factors that could impact the stock (see Risk Factors section).
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Official Resources
Data provided for informational purposes only.
- Limited information available on OTC-listed companies.
- Financial data may not be fully up-to-date.